AVIDITY PARTNERS MANAGEMENT LP
Q1 2024 Form 13-F

DALLAS, TEXAS
CIK 0001791827 · CRD 304628 · SEC-registered investment adviser
$3.1B Reported Value Total

AVIDITY PARTNERS MANAGEMENT LP reports 10 total accounts under management (AUM). There are 10 discretionary accounts valued at $5,268,891,937, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
4 funds · $1.1B gross asset value
Hedge Fund: $1.1B
Source: Form ADV filed 2026-10-30
Reported value
$3.1B
Quarter over quarter
+12.3%
Holdings
87
Top-10 concentration
35.6%

Key People

Form ADV owners & control persons
Michael David Gregory
MANAGING PARTNER, DIRECTOR OF RESEARCH, PRESIDENT OF BUSINESS OPERATIONS
Christopher David Connors
CHIEF FINANCIAL OFFICER
Jose Antonio Santiago
CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2024 13F record

Q1 2024 13F filing summary

Q1 2024 Form 13F portfolio summary
Period of report March 31, 2024
Filed May 15, 2024
Form 13F-HR
Reported value $3.1B
Positions 87
Change in reported value +13.0%
New positions 33
Exited positions 18
Position turnover 48.6%
Top-10 concentration 35.6%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
17 $488.2M
Q2 2026 13F
Filed Aug 14, 2026
45 $624.4M
Q1 2026 13F
Filed May 13, 2026
52 $505.3M
Q4 2025 13F
Filed Feb 13, 2026
39 $346.7M
Q3 2025 13F
Filed Nov 14, 2025
43 $439.4M
Q2 2025 13F
Filed Aug 14, 2025
55 $502.0M
Q1 2025 13F
Filed May 15, 2025
63 $524.7M
Q4 2024 13F
Filed Feb 14, 2025
61 $1.0B
Q3 2024 13F
Filed Nov 14, 2024
81 $2.0B
Q2 2024 13F
Filed Aug 14, 2024
85 $2.4B
Q1 2024 13F
Filed May 15, 2024
87 $3.1B
Q4 2023 13F
Filed Feb 14, 2024
72 $2.7B
Q3 2023 13F
Filed Nov 14, 2023
83 $2.5B
Q2 2023 13F
Filed Aug 14, 2023
93 $2.9B
Q1 2023 13F
Filed May 15, 2023
83 $3.0B
Q4 2022 13F
Filed Feb 14, 2023
84 $4.6B
Q3 2022 13F
Filed Nov 14, 2022
95 $4.9B
Q2 2022 13F
Filed Aug 15, 2022
82 $4.4B
Q1 2022 13F
Filed May 16, 2022
91 $4.8B
Q4 2021 13F
Filed Feb 14, 2022
97 $4.7B

8 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q1 2024

Largest Q1 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 ITCI C INTRA-CELLULAR THERAPIES INC $239.5M 7.72%
2 FUSN FUSION PHARMACEUTICALS INC $138.6M 4.47%
3 BSX BOSTON SCIENTIFIC CORP $134.0M 4.32%
4 ARVN ARVINAS INC $123.2M 3.97%
5 ISRG INTUITIVE SURGICAL INC $90.2M 2.91%
6 DNTH DIANTHUS THERAPEUTICS INC $81.5M 2.63%
7 ACHC ACADIA HEALTHCARE COMPANY IN $79.6M 2.57%
8 NBIX NEUROCRINE BIOSCIENCES INC $74.0M 2.39%
9 NTRA NATERA INC $73.5M 2.37%
10 JAZZ JAZZ PHARMACEUTICALS PLC $70.3M 2.27%
11 AVTR AVANTOR INC $68.9M 2.22%
12 CI THE CIGNA GROUP $67.0M 2.16%
13 MRK MERCK & CO INC $66.2M 2.14%
14 REGN REGENERON PHARMACEUTICALS $65.4M 2.11%
15 CGON CG ONCOLOGY INC $63.9M 2.06%
16 ILMN ILLUMINA INC $63.7M 2.05%
17 THC TENET HEALTHCARE CORP $63.2M 2.04%
18 ALGN ALIGN TECHNOLOGY INC $62.0M 2.0%
19 SNDX SYNDAX PHARMACEUTICALS INC $57.4M 1.85%
20 LLY ELI LILLY & CO $54.5M 1.76%

Values as reported on the Q1 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings